Literature DB >> 31195838

Gene therapy for neurological disorders: challenges and recent advancements.

Stefanie A Pena1, Rahul Iyengar1, Rebecca S Eshraghi1, Nicole Bencie1, Jeenu Mittal1, Abdulrahman Aljohani1, Rahul Mittal1, Adrien A Eshraghi1,2,3.   

Abstract

Major advancements in targeted gene therapy have opened up avenues for the treatment of major neurological disorders through a range of versatile modalities varying from expression of exogenous to suppression of endogenous genes. Recent technological innovations for improved gene sequence delivery have focussed on highly specific viral vector designs, plasmid transfection, nanoparticles, polymer-mediated gene delivery, engineered microRNA and in vivo clustered regulatory interspaced short palindromic repeats (CRISPR)-based therapeutics. These advanced techniques have profound applications in treating highly prevalent neurological diseases and neurodevelopmental disorders including Parkinson's disease, Alzheimer's disease and autism spectrum disorder, as well as rarer diseases such as amyotrophic lateral sclerosis (ALS), spinal muscular atrophy, lysosomal storage diseases, X-linked adrenoleukodystrophy and oncological diseases. In this article, we present an overview of the latest advances in targeted gene delivery and discuss the challenges and future direction of gene therapy in the treatment of neurological disorders.

Entities:  

Keywords:  Autism Spectrum disorder; CRISPER/Cas9 system; Gene therapy; gene delivery; neurological diseases; non-viral vectors; viral vectors

Mesh:

Substances:

Year:  2019        PMID: 31195838     DOI: 10.1080/1061186X.2019.1630415

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  9 in total

Review 1.  CRISPR-Cas9-Mediated Gene Therapy in Neurological Disorders.

Authors:  Lihong Guan; Yawei Han; Ciqing Yang; Suxiang Lu; Jiang Du; Han Li; Juntang Lin
Journal:  Mol Neurobiol       Date:  2021-11-23       Impact factor: 5.590

2.  Engineered AAVs for non-invasive gene delivery to rodent and non-human primate nervous systems.

Authors:  Xinhong Chen; Sripriya Ravindra Kumar; Cameron D Adams; Daping Yang; Tongtong Wang; Damien A Wolfe; Cynthia M Arokiaraj; Victoria Ngo; Lillian J Campos; Jessica A Griffiths; Takako Ichiki; Sarkis K Mazmanian; Peregrine B Osborne; Janet R Keast; Cory T Miller; Andrew S Fox; Isaac M Chiu; Viviana Gradinaru
Journal:  Neuron       Date:  2022-05-27       Impact factor: 18.688

3.  Altered Blood Brain Barrier Permeability and Oxidative Stress in Cntnap2 Knockout Rat Model.

Authors:  Idil Memis; Rahul Mittal; Emily Furar; Isaiah White; Rebecca S Eshraghi; Jeenu Mittal; Adrien A Eshraghi
Journal:  J Clin Med       Date:  2022-05-11       Impact factor: 4.964

Review 4.  Therapeutic Strategies for Mutant SPAST-Based Hereditary Spastic Paraplegia.

Authors:  Neha Mohan; Liang Qiang; Gerardo Morfini; Peter W Baas
Journal:  Brain Sci       Date:  2021-08-18

Review 5.  Strategies for High-Efficiency Mutation Using the CRISPR/Cas System.

Authors:  Shuying Feng; Zilong Wang; Aifang Li; Xin Xie; Junjie Liu; Shuxuan Li; Yalan Li; Baiyan Wang; Lina Hu; Lianhe Yang; Tao Guo
Journal:  Front Cell Dev Biol       Date:  2022-02-07

6.  A brain glioma gene delivery strategy by angiopep-2 and TAT-modified magnetic lipid-polymer hybrid nanoparticles.

Authors:  Lanxin Qiao; Yu Qin; Yaxin Wang; Yi Liang; Dunwan Zhu; Wei Xiong; Lu Li; Di Bao; Linhua Zhang; Xu Jin
Journal:  RSC Adv       Date:  2020-11-13       Impact factor: 4.036

Review 7.  Using the Intranasal Route to Administer Drugs to Treat Neurological and Psychiatric Illnesses: Rationale, Successes, and Future Needs.

Authors:  Andrew Lofts; Fahed Abu-Hijleh; Nicolette Rigg; Ram K Mishra; Todd Hoare
Journal:  CNS Drugs       Date:  2022-06-27       Impact factor: 6.497

8.  Cross-species efficacy of enzyme replacement therapy for CLN1 disease in mice and sheep.

Authors:  Hemanth R Nelvagal; Samantha L Eaton; Sophie H Wang; Elizabeth M Eultgen; Keigo Takahashi; Steven Q Le; Rachel Nesbitt; Joshua T Dearborn; Nicholas Siano; Ana C Puhl; Patricia I Dickson; Gerard Thompson; Fraser Murdoch; Paul M Brennan; Mark Gray; Stephen N Greenhalgh; Peter Tennant; Rachael Gregson; Eddie Clutton; James Nixon; Chris Proudfoot; Stefano Guido; Simon G Lillico; C Bruce A Whitelaw; Jui-Yun Lu; Sandra L Hofmann; Sean Ekins; Mark S Sands; Thomas M Wishart; Jonathan D Cooper
Journal:  J Clin Invest       Date:  2022-10-17       Impact factor: 19.456

Review 9.  Induced Pluripotent Stem Cells (iPSCs) and Gene Therapy: A New Era for the Treatment of Neurological Diseases.

Authors:  Giulia Paolini Sguazzi; Valentina Muto; Marco Tartaglia; Enrico Bertini; Claudia Compagnucci
Journal:  Int J Mol Sci       Date:  2021-12-20       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.